Clinical ResearchHeart Rhythm DisordersMajor Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
Key Words
Abbreviations and Acronyms
Cited by (0)
The ARISTOTLE trial was supported by Bristol-Myers Squibb and Pfizer. Dr. Hylek is a consultant with, receives travel support from, and is an adjudication committee member with Bristol-Myers Squibb, Daiichi Sankyo, Merck, Ortho-McNeil, Johnson & Johnson, and Pfizer; and has received lecture fees from Boehringer Ingelheim. Dr. Held has received grants from AstraZeneca, Merck, GlaxoSmithKline, Roche, and Bristol-Myers Squibb; is on the membership advisory board for AstraZeneca; and has received honoraria from AstraZeneca. Dr. Alexander has received grants from Bristol-Myers Squibb, Merck, and Regado Biosciences; travel support from Bristol-Myers Squibb; and consulting fees from Bristol-Myers Squibb, Pfizer, Merck, AstraZeneca, Boehringer Ingelheim, Ortho-McNeil-Janssen Pharmaceuticals, PolyMedix, Regado Biosciences, Bayer, and Daiichi Sankyo. Dr. Lopes has received grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo; and consulting fees from Bristol-Myers Squibb, Pfizer, Bayer, and Janssen Research & Development, LLC.
Dr. De Caterina is a steering committee member, a national coordinator for Italy, coauthor of the APPRAISE-2, ARISTOTLE, AVERROES studies, and coauthor of European Society of Cardiology Guidelines on Atrial Fibrillation; and has received fees, honoraria, and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo. Dr. Huber has received lecture fees from AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Bayer, Daiichi Sankyo, and Sanofi-Aventis. Dr. Steg has received travel support from Bristol-Myers Squibb; is on the membership boards of Bayer, Bristol-Myers Squibb/Pfizer, AstraZeneca, and Boehringer Ingelheim; has received consulting fees from Bristol-Myers Squibb, Eisai, Ablynx, Amarin, Astellas, Eli Lilly, Medtronic, Novartis, Roche, Servier, The Medicines Company, Sanofi, and AstraZeneca; grants from Servier, Sanofi, and New York University School of Medicine; and lecture fees from Pfizer, Amgen, Otsuka, and Aterovax. Dr. Hanna is an employee of Bristol-Myers Squibb and receives stock as part of compensation. Dr. Wallentin has received grants from AstraZeneca, Merck, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and GlaxoSmithKline; consulting fees from Merck & Co, Regado Biosciences, Evolva, Portola, C.S.L. Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Merck & Co; honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Merck & Co; and travel support from AstraZeneca and Bristol-Myers Squibb/Pfizer. Dr. Granger has received grants from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck & Co, Pfizer, Sanofi-Aventis, Takeda, and The Medicines Company; and consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Novartis Pharmaceutical Company, Lilly, Pfizer, Sanofi-Aventis, Takeda, The Medicines Company, and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.